Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 70 of 70 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
RET fusion	lung non-small cell carcinoma	sensitive	RET Inhibitor	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 64% (64/105) in patients with RET fusion-positive non-small cell lung cancer, with a median duration of response of 17.5 months, ORR was 85% (33/39) and 91% (10/11) in previously treated patients and patients with measurable CNS metastasis, respectively (PMID: 32846060; NCT03157128).	detail... 32846060 detail...
RET fusion	thyroid cancer	sensitive	RET Inhibitor	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate of 79% (15/19), including one complete and 14 partial responses, with a median response duration of 18.4 months, and median progression-free survival of 20.1 months in adult and pediatric patients 12 years and older with RET fusion-positive thyroid cancer who were previously treated (PMID: 32846061; NCT03157128).	detail... detail... 32846061
RET fusion	lung non-small cell carcinoma	sensitive	RET Inhibitor	Pralsetinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (ARROW) that supported FDA approval, Gavreto (pralsetinib) treatment was well-tolerated, resulting in an objective response rate of 61% (53/87) and 70% (19/27) in previously treated and treatment-naive patients with RET fusion-positive non-small cell lung cancer, respectively (PMID: 34118197; NCT03037385).	detail... 34118197 detail...
RET fusion	Advanced Solid Tumor	sensitive	RET Inhibitor	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate of 44% (18/41, 2 complete responses, 16 partial responses), a clinical benefit rate of 63% (26/41), a median duration of response of 24.5 months, and a median progression-free survival of 13.2 months in patients with RET fusion-positive advanced solid tumors (PMID: 36108661; NCT03157128).	36108661 detail...
RET fusion	Advanced Solid Tumor	sensitive	RET Inhibitor	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-121) that supported FDA approval, Retevmo (selpercatinib) treatment was safe in pediatric patients of 2 years or older with solid tumors harboring RET fusion (n=2) or mutations (n=9), and resulted in unconfirmed partial responses in 4 patients, stable disease in 6 patients (two lasting >/=16 weeks) (JCO 39, 10009-10009(2021); NCT03899792).	detail... detail... detail...
RET fusion	thyroid cancer	sensitive	RET Inhibitor	Selpercatinib	FDA approved - On Companion Diagnostic	Actionable	In a Phase I/II trial (LIBRETTO-121) that supported FDA approval, Retevmo (selpercatinib) treatment was safe in pediatric patients of 2 years or older with solid tumors (8 medullary thyroid cancer, 2 papillary thyroid cancer, 1 osteosarcoma) harboring RET fusion (n=2) or mutations (n=9), and resulted in unconfirmed partial responses in 4 patients, stable disease in 6 patients (two lasting >/=16 weeks) (JCO 39, 10009-10009(2021); NCT03899792).	detail... detail... detail...
RET fusion	thyroid cancer	sensitive	RET Inhibitor	Pralsetinib	FDA approved	Actionable	In a Phase I/II trial (ARROW) that supported FDA approval, Gavreto (pralsetinib) treatment was well-tolerated, and resulted in an overall response rate (ORR) of 89% (8/9) in patients with advanced or metastatic RET fusion-positive thyroid cancer, with a median duration of response of 14.5 months, and 67% of responding patients continuing treatment (PMID: 34118198; NCT03037385).	34118198 detail...
RET fusion	papillary thyroid carcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with papillary thyroid carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	follicular thyroid carcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with follicular thyroid carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	oncocytic carcinoma of the thyroid	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with thyroid Hurthle cell carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	medullary thyroid carcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with medullary thyroid carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	anaplastic thyroid carcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as neoadjuvant or systemic therapy for patients with anaplastic thyroid carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	papillary thyroid carcinoma	sensitive	RET Inhibitor	Pralsetinib	Guideline	Actionable	Gavreto (pralsetinib) is included in guidelines as systemic therapy for patients with papillary thyroid carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	medullary thyroid carcinoma	sensitive	RET Inhibitor	Pralsetinib	Guideline	Actionable	Gavreto (pralsetinib) is included in guidelines as systemic therapy for patients with medullary thyroid carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	anaplastic thyroid carcinoma	sensitive	RET Inhibitor	Pralsetinib	Guideline	Actionable	Gavreto (pralsetinib) is included in guidelines as neoadjuvant or systemic therapy for patients with anaplastic thyroid carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	follicular thyroid carcinoma	sensitive	RET Inhibitor	Pralsetinib	Guideline	Actionable	Gavreto (pralsetinib) is included in guidelines for patients with follicular thyroid carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	oncocytic carcinoma of the thyroid	sensitive	RET Inhibitor	Pralsetinib	Guideline	Actionable	Gavreto (pralsetinib) is included in guidelines for patients with thyroid Hurthle cell carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	Erdheim-Chester disease	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as first-line or subsequent-line therapy for patients with Erdheim-Chester disease harboring RET fusions (NCCN.org).	detail...
RET fusion	gallbladder cancer	sensitive	RET Inhibitor	Pralsetinib	Guideline	Actionable	Gavreto (pralsetinib) is included in guidelines as primary (category 2B) and subsequent-line therapy (category 2B) for patients with unresectable or metastatic biliary tract cancer harboring RET fusions, including gallbladder cancer (NCCN.org).	detail...
RET fusion	intrahepatic cholangiocarcinoma	sensitive	RET Inhibitor	Pralsetinib	Guideline	Actionable	Gavreto (pralsetinib) is included in guidelines as primary (category 2B) and subsequent-line therapy (category 2B) for patients with unresectable or metastatic biliary tract cancer harboring RET fusions, including intrahepatic cholangiocarcinoma (NCCN.org).	detail...
RET fusion	extrahepatic bile duct carcinoma	sensitive	RET Inhibitor	Pralsetinib	Guideline	Actionable	Gavreto (pralsetinib) is included in guidelines as primary (category 2B) and subsequent-line therapy (category 2B) for patients with unresectable or metastatic biliary tract cancer harboring RET fusions, including extrahepatic cholangiocarcinoma (NCCN.org).	detail...
RET fusion	differentiated high-grade thyroid carcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with advanced or metastatic differentiated thyroid gland carcinoma harboring RET fusions (PMID: 31549998, PMID: 35491008; ESMO.org).	35491008 31549998 detail...
RET fusion	differentiated high-grade thyroid carcinoma	sensitive	RET Inhibitor	Pralsetinib	Guideline	Actionable	Gavreto (pralsetinib) is included in guidelines for adult or pediatric patients 12 years or older with radioactive iodine-refractory, advanced or metastatic differentiated thyroid gland carcinoma harboring RET fusions (PMID: 31549998, PMID: 35491008; ESMO.org).	35491008 31549998 detail...
RET fusion	hepatocellular carcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as subsequent-line therapy (category 2B) for patients with hepatocellular carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	cholangiocarcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as primary (category 2B) or subsequent-line therapy (category 2A) for patients with unresectable or metastatic cholangiocarcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	small intestine adenocarcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with metastatic small bowel adenocarcinoma with RET fusion (NCCN.org).	detail...
RET fusion	rectum cancer	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with metastatic rectum cancer harboring RET fusion (NCCN.org).	detail...
RET fusion	Adenocarcinoma of Unknown Primary	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with adenocarcinoma of unknown primary harboring RET fusions (NCCN.org).	detail...
RET fusion	Squamous Cell Carcinoma of Unknown Primary	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with squamous cell carcinoma of unknown primary harboring RET fusions (NCCN.org).	detail...
RET fusion	colon cancer	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with metastatic colon cancer harboring RET fusions (NCCN.org).	detail...
RET fusion	pancreatic adenocarcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as first-line therapy for pancreatic adenocarcinoma patients harboring RET fusions with locally advanced or metastatic disease with good (ECOG 0-1) or intermediate (ECOG 2) performance status (PS), and as subsequent therapy for patients with locally advanced, metastatic, or recurrent disease with good PS (NCCN.org).	detail...
RET fusion	cervical cancer	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as second-line or subsequent therapy for patients with cervical cancer harboring RET fusions (NCCN.org).	detail...
RET fusion	salivary gland cancer	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with recurrent, unresectable, or metastatic salivary gland tumors harboring RET fusions (NCCN.org).	detail...
RET fusion	neuroendocrine tumor	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with unresectable or metastatic extrapulmonary poorly differentiated neuroendocrine carcinoma, large or small cell carcinoma, or mixed neuroendocrine/non-neuroendocrine neoplasms harboring RET fusions who have progressed on or following prior treatment (NCCN.org).	detail...
RET fusion	ovary epithelial cancer	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as systemic therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer harboring a RET fusion (NCCN.org).	detail...
RET fusion	sarcoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as first-line therapy for patients with advanced or metastatic soft tissue sarcoma harboring RET fusions (NCCN.org).	detail...
RET fusion	esophagus squamous cell carcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as second-line or subsequent therapy for patients with locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	esophagus adenocarcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as second-line or subsequent therapy for patients with locally advanced, recurrent, or metastatic esophageal adenocarcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	gastroesophageal junction adenocarcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as second-line or subsequent therapy for patients with locally advanced, recurrent, or metastatic gastroesophageal junction adenocarcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	stomach cancer	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as second-line or subsequent therapy for patients with unresectable locally advanced, recurrent, or metastatic gastric cancer harboring RET fusion (NCCN.org). (NCCN.org).	detail...
RET fusion	ampulla of Vater adenocarcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as first-line or subsequent therapy for patients with metastatic ampullary adenocarcinoma harboring RET fusions (NCCN.org).	detail...
RET fusion	lung non-small cell carcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as a first-line therapy for patients with metastatic non-small cell lung cancer harboring RET fusions (PMID: 36872130; ESMO.org).	36872130 detail...
RET fusion	lung non-small cell carcinoma	sensitive	RET Inhibitor	Pralsetinib	Guideline	Actionable	Gavreto (pralsetinib) is included in guidelines as a first-line therapy for patients with metastatic non-small cell lung cancer harboring RET fusions (PMID: 36872130; ESMO.org).	detail... 36872130
RET fusion	gallbladder cancer	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as primary (category 2B) and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer harboring RET fusions, including gallbladder cancer (NCCN.org).	detail...
RET fusion	intrahepatic cholangiocarcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as primary (category 2B) and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer harboring RET fusions, including intrahepatic cholangiocarcinoma (NCCN.org).	detail...
RET fusion	extrahepatic bile duct carcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as primary (category 2B) and subsequent-line therapy for patients with unresectable or metastatic biliary tract cancer harboring RET fusions, including extrahepatic cholangiocarcinoma (NCCN.org).	detail...
RET fusion	vaginal carcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as second-line or subsequent therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma harboring an RET fusion (NCCN.org).	detail...
RET fusion	biliary tract cancer	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) for biliary tract cancer patients harboring RET fusions who have progressed on or are intolerant of prior therapies (PMID: 39232586; ESMO.org).	detail... 39232586
RET fusion	breast cancer	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines for patients with recurrent unresectable or stage IV (M1) breast cancer harboring RET fusions (NCCN.org).	detail...
RET fusion	uterine corpus sarcoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as first-kine therapy for patients with advanced, recurrent/metastatic, or inoperable uterine sarcomas harboring RET fusions (NCCN.org).	detail...
RET fusion	biliary tract cancer	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in guidelines as second or later-line therapy for patients with biliary tract cancer harboring RET fusions (PMID: 39864891; ESMO.org).	detail... 39864891
RET fusion	lung non-small cell carcinoma	sensitive	RET Inhibitor	Selpercatinib	Guideline	Actionable	Retevmo (selpercatinib) is included in the Pan-Asian Guidelines Adaptation (PAGA) as first-line therapy for advanced and metastatic non-small cell lung cancer patients with RET fusions (PMID: 39615406; ESMO.org).	detail... 39615406
RET fusion	lung non-small cell carcinoma	sensitive	RET Inhibitor	Selpercatinib	Phase III	Actionable	In a Phase III trial (LIBRETTO-431), first-line Retevmo (selpercatinib) treatment resulted in superior median progression-free survival (PFS) compared to platinum-based chemotherapy with (24.8 vs 11.2 mo, HR=0.46, p<0.001) or without ((24.8 vs 11.2 mo, HR=0.48, p<0.001) Keytruda (pembrolizumab) in advanced non-small cell lung cancer patients harboring a RET fusion, and improved intracranial (IC) response rate (82.4% vs 58.3%) and median IC PFS (16.1 vs 10.4 mo) (PMID: 38807655; NCT04194944).	38807655
RET fusion	lung non-small cell carcinoma	sensitive	RET Inhibitor	Vandetanib	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetanib) treatment resulted in a disease control rate of 88% (15/17), median progression-free survival (PFS) of 4.7 months, and partial response in 53% (9/17) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9012)).	detail...
RET fusion	lung non-small cell carcinoma	sensitive	RET Inhibitor	Vandetanib	Phase II	Actionable	In a Phase II trial, Caprelsa (vandetanib) treatment resulted in partial remission in 17% (3/18) and stable disease in 44% (8/18) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9013)).	detail...
RET fusion	papillary thyroid carcinoma	sensitive	RET Inhibitor	Pralsetinib	Phase Ib/II	Actionable	In a Phase I/II trial (ARROW), Gavreto (pralsetinib) treatment was well-tolerated, resulted in an objective response rate of 75% (9/12) and a median duration of response of 14.5 months in patients with RET fusion positive papillary thyroid cancer (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 109-109; NCT03037385).	detail...
RET fusion	Advanced Solid Tumor	predicted - sensitive	RET Inhibitor	Pralsetinib	Phase Ib/II	Actionable	In a Phase I/II trial (ARROW), Gavreto (pralsetinib) treatment was well tolerated in patients with advanced solid tumors harboring RET fusions, and led to an overall response rate of 57% (13/23, 3 complete and 10 partial responses), a clinical benefit rate of 70% (16/23), a disease control rate of 83% (19/23), a median duration of response of 11.7 months, a median progression-free survival of 7.4 months, and a median overall survival of 13.6 months (PMID: 35962206; NCT03037385).	35962206
RET fusion	papillary thyroid carcinoma	sensitive	RET Inhibitor	Selpercatinib	Phase I	Actionable	In a Phase I trial, Retevmo (selpercatinib) treatment resulted in an objective response rate of 83% (5/6) in RET fusion-positive papillary thyroid cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128).	detail...
RET fusion	lung non-small cell carcinoma	predicted - sensitive	RET Inhibitor	HS-10365	Phase I	Actionable	In a Phase I trial, HS-10365 treatment demonstrated safety and resulted in a response rate of 70% (21/30) and a disease control rate of 96.7% (29/30) in patients with non-small cell lung cancer harboring RET fusions (Cancer Res (2023) 83 (8_Supplement): CT201; NCT05207787).	detail...
RET fusion	lung non-small cell carcinoma	sensitive	RET Inhibitor	SY-5007	Phase I	Actionable	In a Phase I trial, SY-5007 therapy was tolerable and led to an objective response rate (ORR) of 57.8% (67/116, 67 partial responses), disease control rate (DCR) of 95.7% (111/116), and median progression-free survival of 21.1 mo in advanced solid tumor patients with RET fusions or alterations, and an ORR of 64.1% (41/64) and DCR of 96.9% (62/64) at the phase II dose in non-small cell lung cancer patients with KIF5B (n=51), CCDC6 (n=12), NCOA4 (n=1), or other RET fusions (n=4) (PMID: 39489747; NCT05278364).	39489747
RET fusion	lung non-small cell carcinoma	predicted - sensitive	RET Inhibitor	Zeteletinib	Phase I	Actionable	In a Phase I trial, Zeteletinib treatment resulted in an objective response rate (ORR) of 33% (18/54) in patients with RET-altered advanced solid tumors including an ORR of 33% (10/30) in non-small cell lung cancer patients harboring a RET fusion, an ORR of 44% (7/16) in patients with medullary thyroid cancer harboring RET mutations, and a partial response in a pancreatic cancer patient (J Clin Oncol 2021 39: 15_suppl, 3008; NCT03780517).	detail...
RET fusion	lung non-small cell carcinoma	unknown		unspecified immune checkpoint inhibitor	Clinical Study - Cohort	Actionable	In a retrospective clinical study, patients with non-small cell lung cancer harboring rare targetable drivers (RTD) (BRAF, ERBB2/3, RET, MET, ROS1, NTRK) who received immune checkpoint inhibitors (ICI) achieved longer median overall survival (mOS) (32 vs 13 mo, p=0.01) compared to those who did not receive ICI, mOS was 25.7 mo in patients harboring RET fusions (n=4), although RTD type was not associated with OS in a univariate analysis (PMID: 30268448).	30268448
RET fusion	lung non-small cell carcinoma	sensitive	RET Inhibitor	Pralsetinib	Clinical Study	Actionable	In a retrospective study, Gavreto (pralsetinib) treatment resulted in an objective response rate (ORR) of 61% (39/59, 2 complete responses (CR), 37 partial responses (PR)) and a disease control rate (DCR) of 79.7% in non-small cell lung cancer patients harboring RET fusions, and an intracranial ORR of 66.7% (4/6, 3 CR and 1 PR), an intracranial DCR of 100% in patients with measurable brain metastases (PMID: 36379124).	36379124
RET fusion	lung non-small cell carcinoma	sensitive	RET Inhibitor	Pralsetinib	Clinical Study	Actionable	In a retrospective study, Gavreto (pralsetinib) treatment resulted in an overall response rate of 55.6%, a disease control rate of 72.2%, a median progression-free survival of 10.7 months, and overall survival of 21.2 months in patients with metastatic non-small cell lung cancer harboring a RET fusion (n=36) including KIF5B-RET (n=13) and CCDC6-RET (n=2) (PMID: 39241296).	39241296
RET fusion	pancreatic cancer	predicted - sensitive	RET Inhibitor	Pralsetinib	Case Reports/Case Series	Actionable	In a Phase I/II trial (ARROW), Gavreto (pralsetinib) treatment was well-tolerated, resulted in a partial response in 2 of 2 patients with RET fusion positive pancreatic cancer, with a duration of response of 5.5 and 7.4 months, respectively (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 109-109; NCT03037385).	detail...
RET fusion	intrahepatic cholangiocarcinoma	sensitive	RET Inhibitor	Pralsetinib	Case Reports/Case Series	Actionable	In a Phase I/II trial (ARROW), Gavreto (pralsetinib) treatment was well-tolerated, resulted in a partial response in a patient with RET fusion-positive intrahepatic cholangiocarcinoma, with a duration of response of 7.5 months (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 109-109; NCT03037385).	detail...
RET fusion	colon cancer	predicted - sensitive	RET Inhibitor	Pralsetinib	Case Reports/Case Series	Actionable	In a Phase I/II trial (ARROW), Gavreto (pralsetinib) treatment was well-tolerated, resulted in stable disease in 2 patients with RET fusion-positive colon cancer, with a duration of response of 7.3 and 9.3 months, respectively (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 109-109; NCT03037385).	detail...
RET fusion	pancreatic cancer	predicted - sensitive	RET Inhibitor	Selpercatinib	Case Reports/Case Series	Actionable	In a Phase I/II trial (LIBRETTO-001), Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 43.9% (18/41, 2 complete responses, 16 partial responses) with a median duration of response (mDOR) of 24.5 months in patients with RET fusion-positive advanced or metastatic solid tumors, and ORR and mDOR in patients with pancreatic cancer were 54.5% (6/11) and not reached, respectively (PMID: 36108661; NCT03157128).	36108661
RET fusion	colon cancer	sensitive	RET Inhibitor	Selpercatinib	Case Reports/Case Series	Actionable	In a Phase I/II trial (LIBRETTO-001), Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 43.9% (18/41, 2 complete responses, 16 partial responses) with a median duration of response (mDOR) of 24.5 months in patients with RET fusion-positive advanced or metastatic solid tumors, and ORR and mDOR in patients with colon cancer were 20.0% (2/10) and 9.4 months, respectively (PMID: 36108661; NCT03157128).	36108661
RET fusion	pancreatic cancer	predicted - sensitive	RET Inhibitor	Zeteletinib	Case Reports/Case Series	Actionable	In a Phase I trial, Zeteletinib treatment resulted in an objective response rate (ORR) of 33% (18/54) in patients with RET-altered advanced solid tumors including an ORR of 33% (10/30) in non-small cell lung cancer patients harboring a RET fusion, an ORR of 44% (7/16) in patients with medullary thyroid cancer harboring RET mutations, and a partial response in a pancreatic cancer patient (J Clin Oncol 2021 39: 15_suppl, 3008; NCT03780517).	detail...

Showing 1 to 70 of 70 entries

Filter rows:

Profile Name	RET fusion
Gene Variant Detail	RET fusion (unknown)
Relevant Treatment Approaches	RET Inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting